Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.
Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Semin Thromb Hemost. 2019 Mar;45(2):150-156. doi: 10.1055/s-0039-1678720. Epub 2019 Feb 11.
Patients with acute spinal cord injury (SCI) have the highest risk of venous thromboembolism (VTE) among hospitalized patients. The incidence of total deep vein thrombosis ranges from 50 to 100% in untreated patients and pulmonary embolism is the third most common cause of mortality in these patients. The pathophysiology of the increased risk of VTE is explained by venous stasis after injury, endothelial vessel wall injury from surgery, and a hypercoagulable state associated with trauma. The current thromboprophylaxis options are limited, with low-molecular-weight heparin (LMWH) being the current standard of care. LMWH is commonly administered for 3 months, during which period the risk of VTE is especially high. Some uncertainty exists regarding the optimal timing to initiate pharmacological thromboprophylaxis and the best regimen of LMWH prophylaxis. High-quality data are currently lacking in thromboprophylaxis in patients with SCI. Many questions in this area remain to be answered, which are described in this narrative review.
急性脊髓损伤 (SCI) 患者在住院患者中静脉血栓栓塞症 (VTE) 的风险最高。未经治疗的患者总深静脉血栓形成的发生率为 50%至 100%,肺栓塞是这些患者死亡的第三大常见原因。VTE 风险增加的病理生理学解释为损伤后静脉淤滞、手术导致的血管内皮壁损伤以及与创伤相关的高凝状态。目前的血栓预防选择有限,低分子量肝素 (LMWH) 是目前的护理标准。LMWH 通常给药 3 个月,在此期间 VTE 的风险特别高。关于开始药物性血栓预防的最佳时机和 LMWH 预防的最佳方案存在一些不确定性。目前在 SCI 患者的血栓预防方面缺乏高质量的数据。该领域仍有许多问题需要解答,本文对这些问题进行了叙述性综述。